欧洲放射肿瘤学会放射肿瘤实践咨询委员会关于早期乳腺癌外照射放疗患者选择及剂量分割的共识建议
该共识指出中度大分割放疗可用于任何患者的全乳、胸壁(伴或不伴重建)及淋巴结区域;超分割(五次)可用于非淋巴结区域乳腺或胸壁(不伴重建)放疗,可作为标准治疗或在随机试验或前瞻性队列中实施。
要点
- 中度大分割放疗可提供给任何患者用于全乳、胸壁(伴或不伴重建)及淋巴结区域。
- 超分割(五次)可提供给非淋巴结区域乳腺或胸壁(不伴重建)放疗,作为标准治疗或在随机试验或前瞻性队列中。
- 共识旨在促进循证乳腺外照射放疗的公平可及并推动新证据转化为日常实践。
核心结论
- 中度大分割放疗可提供给任何患者用于全乳、胸壁(伴或不伴重建)及淋巴结区域。
- 超分割(五次)可提供给非淋巴结区域乳腺或胸壁(不伴重建)放疗,作为标准治疗或在随机试验或前瞻性队列中。
研究设计与样本
- 欧洲放射肿瘤学会放射肿瘤实践咨询委员会共识。
主要发现
- 测试中度大分割乳腺放疗的高质量随机临床试验已明确显示局部控制和生存至少与每日2 Gy分次相当,且正常组织毒性相似或降低。
- FAST-Forward五次分次随机试验的新证据以及COVID-19大流行期间全球放射肿瘤界团结并快速重新思考大分割实施的需要,促成了转折点。
关键数值与推荐
- 中度大分割放疗可提供给任何患者用于全乳、胸壁(伴或不伴重建)及淋巴结区域。
- 超分割(五次)可提供给非淋巴结区域乳腺或胸壁(不伴重建)放疗,作为标准治疗或在随机试验或前瞻性队列中。
临床怎么用
- 中度大分割放疗可提供给任何患者用于全乳、胸壁(伴或不伴重建)及淋巴结区域。
- 超分割(五次)可提供给非淋巴结区域乳腺或胸壁(不伴重建)放疗,作为标准治疗或在随机试验或前瞻性队列中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-quality randomised clinical trials testing moderately fractionated breast radiotherapy have clearly shown that local control and survival is at least as effective as with 2 Gy daily fractions with similar or reduced normal tissue toxicity. Fewer treatment visits are welcomed by patients and their families, and reduced fractions produce substantial savings for health-care systems. Implementation of hypofractionation, however, has moved at a slow pace. The oncology community have now reached an inflection point created by new evidence from the FAST-Forward five-fraction randomised trial and catalysed by the need for the global radiation oncology community to unite during the COVID-19 pandemic and rapidly rethink hypofractionation implementation. The aim of this paper is to support equity of access for all patients to receive evidence-based breast external beam radiotherapy and to facilitate the translation of new evidence into routine daily practice. The results from this European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus state that moderately hypofractionated radiotherapy can be offered to any patient for whole breast, chest wall (with or without reconstruction), and nodal volumes. Ultrafractionation (five fractions) can also be offered for non-nodal breast or chest wall (without reconstruction) radiotherapy either as standard of care or within a randomised trial or prospective cohort. The consensus is timely; not only is it a pragmatic framework for radiation oncologists, but it provides a measured proposal for the path forward to influence policy makers and empower patients to ensure equity of access to evidence-based radiotherapy.
引用
- Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022. PMID: 34973228. doi:10.1016/S1470-2045(21)00539-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。